Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,858.00
Bid: 6,847.00
Ask: 6,850.00
Change: 1.00 (0.01%)
Spread: 3.00 (0.04%)
Open: 6,800.00
High: 6,921.00
Low: 6,779.00
Yest. Close: 6,857.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 1-Bristol immune drug shows strong effect in melanoma study

* 32 percent response rate in patients treated with Opdivo * 95 percent of responders still benefiting after 6 months * Lung cancer results with Opdivo expected later in year (Adds detail on forthcoming lung cancer study findings) By Ben Hirschler MADRID, Sept 29 (Reuter

29 Sep 14 08:47

London pre-open: Flat start predicted for FTSE

London's blue chips are set to open flat on Monday morning ahead of a very busy week both at home and abroad, particularly in the latter half. City sources predict the FTSE 100 will open unchanged from Friday's close of 6,649. "European markets are set for an incredibly busy week as we see the f

29 Sep 14 07:42

AstraZeneca Updates On Oncology Pipeline Progression At ESMO Congress

29 Sep 14 07:10

Astrazeneca reports latest drug developments

Drugs maker Astrazeneca has presented data from its pipeline of cancer treatment studies at the 2014 European Society of Medical Oncology Congress. The FTSE 100 group presented preliminary data from its ongoing phase I study of MEDI4736, which is being tested in combination with a drug called tre

29 Sep 14 07:09

Bristol immune drug shows strong effect in melanoma study

By Ben Hirschler MADRID, Sept 29 (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option. The data has

29 Sep 14 07:00

Failed cancer vaccines might live again with new immune drugs

By Ben Hirschler MADRID, Sept 28 (Reuters) - Using vaccines to fight cancer is a field littered with failures but experts believe it is possible the approach could get a new lease of life if such shots are combined with a new class of drugs called checkpoint inhibitors. Unlike traditi

28 Sep 14 09:10

Merck drug extends immune system fight to stomach cancer

* Keytruda shrinks tumours in small gastric cancer study * Evidence of immunotherapy's expanding role in cancer * Merck plans to start Phase II study in first quarter 2015 By Ben Hirschler MADRID, Sept 28 (Reuters) - Merck & Co's drug Keytruda, the first in a new wave of i

28 Sep 14 07:15

No benefit from continued use of AstraZeneca's Iressa drug

By Ben Hirschler MADRID, Sept 28 (Reuters) - Continuing to give AstraZeneca's drug Iressa plus chemotherapy to lung cancer patents whose disease has worsened after previously taking the medicine on its own does not provide any benefit. Some doctors had hoped that extending the use of

28 Sep 14 06:59

UPDATE 1-Early data promising for AstraZeneca cancer drug combination

* MEDI4736, tremelimumab combination tested in lung cancer * Safety data reported for 24 patients, efficacy for 18 * AstraZeneca says tolerability profile encouraging * Objective response rate in patients 28 percent (Adds comments from researcher, paragraphs 5 and 11) By

27 Sep 14 11:45

Early data promising for AstraZeneca cancer drug combination

* MEDI4736, tremelimumab combination tested in lung cancer * Safety data reported for 24 patients, efficacy for 18 * AstraZeneca says tolerability profile encouraging * Objective response rate in patients 28 percent By Ben Hirschler MADRID, Sept 27 (Reuters) - Early

27 Sep 14 10:44

Bristol immunotherapy gets 6-month U.S. FDA review for melanoma

Sept 26 (Reuters) - The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the company said on Friday. The FDA decision is due by March 30, 2015.<

26 Sep 14 21:08

London close: Stocks end with modest gain, but down on week overall

UK stocks ended the final session of the week with a modest rise, although on the week the index was significantly lower. The FTSE 100 closed 9.68 points higher at 6,649.39. Markets are concerned about mounting geopolitical tensions, with the government due to take a vote on whether to participate

26 Sep 14 16:48

FTSE 100 movers: Easyjet shares take off thanks to comments from Jefferies

Shares in Easyjet flew higher after Jefferies said the airline was situated to benefit from the recent problems with Air France-KLM, which has been forced to cancel numerous flights due to pilot strike action. The broker also predicted the group would have a positive finish to the year. Astrazeneca

26 Sep 14 16:23

Astrazeneca receives positive feedback for Moventig

Astrazeneca shares strained higher on Friday after the company received positive feedback for Moventig, its new treatment for opioid-induced constipation. The committee for Medicinal Products for Human Use of the European Medicines Agency said it had formed a positive opinion on the drug, which has

26 Sep 14 12:36

BUZZ-U.S. Stocks on the Move-BlackBerry, AcelRx, Repros, Diamond Foods, Nike

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index futures were inching higher on Friday after

26 Sep 14 12:35

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.